Vitiligo Supportive Care Protocol

Vitiligo is an autoimmune condition where the immune system attacks melanocytes (pigment-producing cells), causing white patches on the skin. It affects about 1% of the population worldwide and can occur at any age.

TYPES:

•Non-segmental (generalized): Most common; symmetrical patches; can spread

•Segmental: One side of body; usually stable; often in younger people

•Universal: Most of body affected (rare)

ASSOCIATED CONDITIONS:

•Thyroid disease (especially Hashimoto's)

•Type 1 diabetes

•Addison's disease

•Pernicious anemia

•Other autoimmune conditions

WHAT TRIGGERS IT:

•Genetic predisposition

•Autoimmune attack on melanocytes

•Oxidative stress

•Stress (can trigger or worsen)

•Skin trauma (Koebner phenomenon)

•Sunburn

TREATMENT OPTIONS:

•Topical corticosteroids: First-line for localized vitiligo

•Calcineurin inhibitors: Tacrolimus, pimecrolimus (especially for face)

•Phototherapy: NB-UVB is gold standard for widespread disease

•JAK inhibitors: Ruxolitinib cream (Opzelura) - newly approved

•Depigmentation: For very extensive disease (remove remaining pigment)

•Surgical: Grafting for stable, localized disease

SUN PROTECTION:

•Vitiligo patches burn easily

•Use high SPF sunscreen on depigmented areas

•Paradoxically, controlled sun exposure can help with treatment

* Vitamin D is commonly deficient and supports immune regulation.

* B12 and folic acid have been studied for repigmentation.

* Ginkgo biloba shows promise in small studies.

* Antioxidants may help protect remaining melanocytes.

Expected timeline: Repigmentation is slow - takes months. Best results with combination approaches. Supplements are adjunctive to medical treatment.

Clinical Perspective

Vitiligo: Acquired depigmenting disorder from autoimmune melanocyte destruction. Prevalence ~1%. Types: non-segmental (most common, symmetrical, progressive) vs segmental (one dermatome, often stable). Pathogenesis: autoimmune attack, oxidative stress, genetic susceptibility. Associations: thyroid disease (check TSH), other autoimmune conditions.

CRITICAL: Treatments aim to halt progression and induce repigmentation. Topical corticosteroids (first-line for localized). Calcineurin inhibitors (face/sensitive areas). NB-UVB phototherapy for widespread. JAK inhibitors (ruxolitinib cream) - new option. Response slow (months); face/neck respond best; acral areas respond poorly. Supplements are adjunctive - no strong evidence alone; may enhance phototherapy response. Sun protection essential for depigmented areas.

* Vitamin D (C-grade): Immune modulation. Systematic review: (PMID: 28750270). 2000-4000 IU daily. Often deficient.

* B12/Folic Acid (C-grade): Melanocyte support. Systematic review: (PMID: 27450775). B12 1000mcg, FA 5mg daily. Combined with sun exposure.

* Ginkgo Biloba (C-grade): Anti-inflammatory. RCT: (PMID: 23210769). 60-120mg BID. Some repigmentation seen.

* Antioxidants (C-grade): Oxidative stress. Systematic review: (PMID: 23075608). Combination approach.

* Zinc (C-grade): Antioxidant. Review: (PMID: 26845419). 30-50mg daily.

* L-Phenylalanine (C-grade): Melanin precursor. Review: (PMID: 26424423). With UV. Medical supervision needed.

* Copper (C-grade): Tyrosinase cofactor. Review: (PMID: 26729615). 1-2mg daily.

Assessment targets: Extent and activity of disease (VASI score), repigmentation rate, quality of life, associated autoimmune conditions.

Protocol notes: Treatment selection: based on extent, location, activity. Face/neck: respond well; calcineurin inhibitors preferred (avoid steroids long-term on face). Phototherapy: NB-UVB 2-3x weekly; takes 6-12 months; >200 treatments may be needed. Combination: topicals + phototherapy often best. Excimer laser: targeted phototherapy; good for limited areas. JAK inhibitors: ruxolitinib cream (Opzelura) FDA-approved 2022; significant advance. Koebner: avoid skin trauma. Screening: check thyroid annually; consider other autoimmune conditions. Psychological: significant impact; support important; consider dermatology-specific quality of life measures. Camouflage: cosmetic camouflage makeup; self-tanning agents. Depigmentation: for extensive (>50%) stable disease; removes remaining pigment for even appearance. Children: common; usually responds well; avoid long-term steroids. Activity: new/expanding patches, confetti-like depigmentation = active disease.

View All Protocols